What do New Zealands healthcare and aviation have in common? Much, if attending to the way non-funded vaccinations are priced. Indeed, I recently needed a two-course rotavirus vaccine for my little one, only to face the equivalent of a return trip offered as two one-way tickets, crippling overcharges and hidden costs.I got multiple quotes, each bringing about a new piece of information; three times I opted out of vaccination because of the ever increasing costs, only to be brought back in when finding alternative quotes online and internationally.In hindsight, however, the experience makes for an interesting case study and provides a provocative insight into the role that Healthcare may be playing in preventing more parents from taking these vaccinations.Methods The sample is a convenient one: the quotes I got during a two-days quest for GlaxoSmithKlines (GSK) dual-dose Rotarix\u00ae. The data are a retrospective breakdown of costs. Hidden costs were estimated as they became apparent.Results I got 12 quotes, 8 from vaccination centres in the North Island (see top of Table 1), 4 from the web and from an international source (bottom of Table 1). The first column lists the chronological order of each quote, the second column lists the initial quote, the last column lists the things I considered when estimating the full cost, broken down in the remaining columns. Consultation fees (free for children) are excluded. Table 1. Breakdown of real and estimated costs quoted for Rotarix\u00ae in 2013 The costs quoted on the Web were made in different years (2009, 2011, 2012) and may not be representative of costs in 2013. Therefore, all costs are standardised to 2010 referential dollars (r$),1 with 2013 nominal values ($) within parentheses when appropriate. The standard quote for comparison is number VII, the still running discounted vaccine* as described in GSKs Patient Access Programme for Rotarix\u00ae,2 and intended to bring about a reduction of r$66 ($69) to the final cost of the vaccine. Considerations This initial quote was the first firm quote paid for. Afterwards, and prior to ordering, the provider realised it had not charged the vaccine correctly, nor GST, delivery costs and nurse's costs. The initial quote turned out to be for one dose. Hidden costs suspected after reading the providers website. Hidden costs not provided but clarified upon questioning. It does not customarily pass delivery fees as a separate cost. It explicitly quoted the full charge for the dual vaccine as applying to each dose separately. It explicitly quoted two delivery fees (yet the two-doses are delivered bundled together). Final price, including vaccine, delivery and service. It explicitly quoted the vaccine as being on special. Quote after asking the provider whether GSK's 2012 programme2 was still running. Rotarix\u00ae's estimated full cost based on information from GSK.2 Rotarix\u00ae's estimated discounted cost based on information from GSK.2 There was a chance this information was outdated. Final price as reflected on the Spanish Vademecum in 2011,3 including vaccine, delivery and service. Simulation of the cost of Rotarix\u00ae in Spain had it been discounted as in New Zealand. Discussion Rotavirus gastroenteritis is quite common, and most children will get infected by the age of 5 years.4 Of these, 3% will need hospitalisation, 6% will be seen by emergency departments, and 20% will be managed at primary care levels.7 The worst cases will course with severe diarrhoea, vomiting, dehydration, electrolyte disturbance,4 brain damage, disability, even death.5 Yet gastroenteritis is preventable5 and the recommended immunisation,4,8-10although not funded,4 may protect up to 90% of children against subsequent severe infections.6 The number of parents opting for non-funded vaccinations is probably low, yet this number may drop further due to the mismatch between actual costs to providers and final costs to parents. Most of the quotes I got in my quest for vaccination largely surpassed the discounted costs intended by GSK by an average of r$97 ($102). Unreasonable practices among providers were quoting the price of the two doses as applicable to each dose individually, as well as quoting two delivery fees, effectively overcharging both. All-in-all, GSKs intention of improving patients access to Rotarix\u00ae2 by bringing about a reduction in the final price of the vaccine to about r$194 ($204)# seems not to be realised, with the consequent detrimental effects on childrens health and future costs to District Health Boards. Footnotes: * GSKs Patient Access Programme for Rotarix\u00ae will run until at least the end of 2013 (personal communication with Melissa Rich, vaccine product manager for GlaxoSmithKline NZ). # A well-organised provider could bring the total cost down to r$173 ($182) by ordering two sets of vaccines at once and passing on the savings in delivery fees. Jose D Perezgonzalez Lecturer, Massey University Palmerston North, New Zealand
Perezgonzalez JD. Referential NZD based on CPI (2012e). Knowledge. 2013: 69-73.Immunisation Advisory Centre. Rotarix\u00ae Patient Access Programme. 20 December 2011. Retrieved from http://www.immune.org.nz/news/rotarix-patient-access-programme, on 10 March 2013.UBM Medica. Vademecum Internacional 11. 2011. Spain: UBM Medica.Ministry of Health. Immunisation Handbook 2011. 2011. Wellington: Ministry of Health.Paediatric Society position statement on Rotavirus immunisation. January 2013. Retrieved from http://www.paediatrics.org.nz/index.asp?pageID=2145878337, on 13 March 2013.Velazquez FR, Matson DO, Calva JJ, et al. Rotavirus infections in infants as protection against subsequent infections. New England J Med. 1996; 335(14):1022-1028.GlaxoSmithKline. GSK submission to the Health Select Committee inquiry into immunisation. N.d. Retrieved from http://www.google.co.nz/url?sa=t&rct=j&q=&esrc=s&source=web&cd=1&cad=rja&ved=0CDAQFjAA&url=http%3A%2F%2Fwww.parliament.nz%2Fnr%2Frdonlyres%2Fdd8706bb-fe39-45af-a146-aabb34613f3a%2F135723%2F49sche_e..&ei=oCpJUcrvI4iaiAfZnIGYBA&usg=AFQjCNH7QbeIeZXstd4uYhC0Ry0XpeAVng&bvm=bv.44011176,d.aGc, on 11 March 2013.World Health Organization. Immunization, vaccines and biologicals: rotavirus. 12 April 2010. Retrieved fromhttp://www.who.int/immunization/topics/rotavirus/en/index.html, on 8 March 2013.Reid S. The further and future evolution of the New Zealand Immunisation Schedule. NZ Med J. 2012; 125(1354):86-99.Patel MM, Clark AD, Sanderson CFB, et al. Removing the age restrictions for rotavirus vaccination: a benefit-risk analysis. PLOS Med. 2012;
What do New Zealands healthcare and aviation have in common? Much, if attending to the way non-funded vaccinations are priced. Indeed, I recently needed a two-course rotavirus vaccine for my little one, only to face the equivalent of a return trip offered as two one-way tickets, crippling overcharges and hidden costs.I got multiple quotes, each bringing about a new piece of information; three times I opted out of vaccination because of the ever increasing costs, only to be brought back in when finding alternative quotes online and internationally.In hindsight, however, the experience makes for an interesting case study and provides a provocative insight into the role that Healthcare may be playing in preventing more parents from taking these vaccinations.Methods The sample is a convenient one: the quotes I got during a two-days quest for GlaxoSmithKlines (GSK) dual-dose Rotarix\u00ae. The data are a retrospective breakdown of costs. Hidden costs were estimated as they became apparent.Results I got 12 quotes, 8 from vaccination centres in the North Island (see top of Table 1), 4 from the web and from an international source (bottom of Table 1). The first column lists the chronological order of each quote, the second column lists the initial quote, the last column lists the things I considered when estimating the full cost, broken down in the remaining columns. Consultation fees (free for children) are excluded. Table 1. Breakdown of real and estimated costs quoted for Rotarix\u00ae in 2013 The costs quoted on the Web were made in different years (2009, 2011, 2012) and may not be representative of costs in 2013. Therefore, all costs are standardised to 2010 referential dollars (r$),1 with 2013 nominal values ($) within parentheses when appropriate. The standard quote for comparison is number VII, the still running discounted vaccine* as described in GSKs Patient Access Programme for Rotarix\u00ae,2 and intended to bring about a reduction of r$66 ($69) to the final cost of the vaccine. Considerations This initial quote was the first firm quote paid for. Afterwards, and prior to ordering, the provider realised it had not charged the vaccine correctly, nor GST, delivery costs and nurse's costs. The initial quote turned out to be for one dose. Hidden costs suspected after reading the providers website. Hidden costs not provided but clarified upon questioning. It does not customarily pass delivery fees as a separate cost. It explicitly quoted the full charge for the dual vaccine as applying to each dose separately. It explicitly quoted two delivery fees (yet the two-doses are delivered bundled together). Final price, including vaccine, delivery and service. It explicitly quoted the vaccine as being on special. Quote after asking the provider whether GSK's 2012 programme2 was still running. Rotarix\u00ae's estimated full cost based on information from GSK.2 Rotarix\u00ae's estimated discounted cost based on information from GSK.2 There was a chance this information was outdated. Final price as reflected on the Spanish Vademecum in 2011,3 including vaccine, delivery and service. Simulation of the cost of Rotarix\u00ae in Spain had it been discounted as in New Zealand. Discussion Rotavirus gastroenteritis is quite common, and most children will get infected by the age of 5 years.4 Of these, 3% will need hospitalisation, 6% will be seen by emergency departments, and 20% will be managed at primary care levels.7 The worst cases will course with severe diarrhoea, vomiting, dehydration, electrolyte disturbance,4 brain damage, disability, even death.5 Yet gastroenteritis is preventable5 and the recommended immunisation,4,8-10although not funded,4 may protect up to 90% of children against subsequent severe infections.6 The number of parents opting for non-funded vaccinations is probably low, yet this number may drop further due to the mismatch between actual costs to providers and final costs to parents. Most of the quotes I got in my quest for vaccination largely surpassed the discounted costs intended by GSK by an average of r$97 ($102). Unreasonable practices among providers were quoting the price of the two doses as applicable to each dose individually, as well as quoting two delivery fees, effectively overcharging both. All-in-all, GSKs intention of improving patients access to Rotarix\u00ae2 by bringing about a reduction in the final price of the vaccine to about r$194 ($204)# seems not to be realised, with the consequent detrimental effects on childrens health and future costs to District Health Boards. Footnotes: * GSKs Patient Access Programme for Rotarix\u00ae will run until at least the end of 2013 (personal communication with Melissa Rich, vaccine product manager for GlaxoSmithKline NZ). # A well-organised provider could bring the total cost down to r$173 ($182) by ordering two sets of vaccines at once and passing on the savings in delivery fees. Jose D Perezgonzalez Lecturer, Massey University Palmerston North, New Zealand
Perezgonzalez JD. Referential NZD based on CPI (2012e). Knowledge. 2013: 69-73.Immunisation Advisory Centre. Rotarix\u00ae Patient Access Programme. 20 December 2011. Retrieved from http://www.immune.org.nz/news/rotarix-patient-access-programme, on 10 March 2013.UBM Medica. Vademecum Internacional 11. 2011. Spain: UBM Medica.Ministry of Health. Immunisation Handbook 2011. 2011. Wellington: Ministry of Health.Paediatric Society position statement on Rotavirus immunisation. January 2013. Retrieved from http://www.paediatrics.org.nz/index.asp?pageID=2145878337, on 13 March 2013.Velazquez FR, Matson DO, Calva JJ, et al. Rotavirus infections in infants as protection against subsequent infections. New England J Med. 1996; 335(14):1022-1028.GlaxoSmithKline. GSK submission to the Health Select Committee inquiry into immunisation. N.d. Retrieved from http://www.google.co.nz/url?sa=t&rct=j&q=&esrc=s&source=web&cd=1&cad=rja&ved=0CDAQFjAA&url=http%3A%2F%2Fwww.parliament.nz%2Fnr%2Frdonlyres%2Fdd8706bb-fe39-45af-a146-aabb34613f3a%2F135723%2F49sche_e..&ei=oCpJUcrvI4iaiAfZnIGYBA&usg=AFQjCNH7QbeIeZXstd4uYhC0Ry0XpeAVng&bvm=bv.44011176,d.aGc, on 11 March 2013.World Health Organization. Immunization, vaccines and biologicals: rotavirus. 12 April 2010. Retrieved fromhttp://www.who.int/immunization/topics/rotavirus/en/index.html, on 8 March 2013.Reid S. The further and future evolution of the New Zealand Immunisation Schedule. NZ Med J. 2012; 125(1354):86-99.Patel MM, Clark AD, Sanderson CFB, et al. Removing the age restrictions for rotavirus vaccination: a benefit-risk analysis. PLOS Med. 2012;
What do New Zealands healthcare and aviation have in common? Much, if attending to the way non-funded vaccinations are priced. Indeed, I recently needed a two-course rotavirus vaccine for my little one, only to face the equivalent of a return trip offered as two one-way tickets, crippling overcharges and hidden costs.I got multiple quotes, each bringing about a new piece of information; three times I opted out of vaccination because of the ever increasing costs, only to be brought back in when finding alternative quotes online and internationally.In hindsight, however, the experience makes for an interesting case study and provides a provocative insight into the role that Healthcare may be playing in preventing more parents from taking these vaccinations.Methods The sample is a convenient one: the quotes I got during a two-days quest for GlaxoSmithKlines (GSK) dual-dose Rotarix\u00ae. The data are a retrospective breakdown of costs. Hidden costs were estimated as they became apparent.Results I got 12 quotes, 8 from vaccination centres in the North Island (see top of Table 1), 4 from the web and from an international source (bottom of Table 1). The first column lists the chronological order of each quote, the second column lists the initial quote, the last column lists the things I considered when estimating the full cost, broken down in the remaining columns. Consultation fees (free for children) are excluded. Table 1. Breakdown of real and estimated costs quoted for Rotarix\u00ae in 2013 The costs quoted on the Web were made in different years (2009, 2011, 2012) and may not be representative of costs in 2013. Therefore, all costs are standardised to 2010 referential dollars (r$),1 with 2013 nominal values ($) within parentheses when appropriate. The standard quote for comparison is number VII, the still running discounted vaccine* as described in GSKs Patient Access Programme for Rotarix\u00ae,2 and intended to bring about a reduction of r$66 ($69) to the final cost of the vaccine. Considerations This initial quote was the first firm quote paid for. Afterwards, and prior to ordering, the provider realised it had not charged the vaccine correctly, nor GST, delivery costs and nurse's costs. The initial quote turned out to be for one dose. Hidden costs suspected after reading the providers website. Hidden costs not provided but clarified upon questioning. It does not customarily pass delivery fees as a separate cost. It explicitly quoted the full charge for the dual vaccine as applying to each dose separately. It explicitly quoted two delivery fees (yet the two-doses are delivered bundled together). Final price, including vaccine, delivery and service. It explicitly quoted the vaccine as being on special. Quote after asking the provider whether GSK's 2012 programme2 was still running. Rotarix\u00ae's estimated full cost based on information from GSK.2 Rotarix\u00ae's estimated discounted cost based on information from GSK.2 There was a chance this information was outdated. Final price as reflected on the Spanish Vademecum in 2011,3 including vaccine, delivery and service. Simulation of the cost of Rotarix\u00ae in Spain had it been discounted as in New Zealand. Discussion Rotavirus gastroenteritis is quite common, and most children will get infected by the age of 5 years.4 Of these, 3% will need hospitalisation, 6% will be seen by emergency departments, and 20% will be managed at primary care levels.7 The worst cases will course with severe diarrhoea, vomiting, dehydration, electrolyte disturbance,4 brain damage, disability, even death.5 Yet gastroenteritis is preventable5 and the recommended immunisation,4,8-10although not funded,4 may protect up to 90% of children against subsequent severe infections.6 The number of parents opting for non-funded vaccinations is probably low, yet this number may drop further due to the mismatch between actual costs to providers and final costs to parents. Most of the quotes I got in my quest for vaccination largely surpassed the discounted costs intended by GSK by an average of r$97 ($102). Unreasonable practices among providers were quoting the price of the two doses as applicable to each dose individually, as well as quoting two delivery fees, effectively overcharging both. All-in-all, GSKs intention of improving patients access to Rotarix\u00ae2 by bringing about a reduction in the final price of the vaccine to about r$194 ($204)# seems not to be realised, with the consequent detrimental effects on childrens health and future costs to District Health Boards. Footnotes: * GSKs Patient Access Programme for Rotarix\u00ae will run until at least the end of 2013 (personal communication with Melissa Rich, vaccine product manager for GlaxoSmithKline NZ). # A well-organised provider could bring the total cost down to r$173 ($182) by ordering two sets of vaccines at once and passing on the savings in delivery fees. Jose D Perezgonzalez Lecturer, Massey University Palmerston North, New Zealand
Perezgonzalez JD. Referential NZD based on CPI (2012e). Knowledge. 2013: 69-73.Immunisation Advisory Centre. Rotarix\u00ae Patient Access Programme. 20 December 2011. Retrieved from http://www.immune.org.nz/news/rotarix-patient-access-programme, on 10 March 2013.UBM Medica. Vademecum Internacional 11. 2011. Spain: UBM Medica.Ministry of Health. Immunisation Handbook 2011. 2011. Wellington: Ministry of Health.Paediatric Society position statement on Rotavirus immunisation. January 2013. Retrieved from http://www.paediatrics.org.nz/index.asp?pageID=2145878337, on 13 March 2013.Velazquez FR, Matson DO, Calva JJ, et al. Rotavirus infections in infants as protection against subsequent infections. New England J Med. 1996; 335(14):1022-1028.GlaxoSmithKline. GSK submission to the Health Select Committee inquiry into immunisation. N.d. Retrieved from http://www.google.co.nz/url?sa=t&rct=j&q=&esrc=s&source=web&cd=1&cad=rja&ved=0CDAQFjAA&url=http%3A%2F%2Fwww.parliament.nz%2Fnr%2Frdonlyres%2Fdd8706bb-fe39-45af-a146-aabb34613f3a%2F135723%2F49sche_e..&ei=oCpJUcrvI4iaiAfZnIGYBA&usg=AFQjCNH7QbeIeZXstd4uYhC0Ry0XpeAVng&bvm=bv.44011176,d.aGc, on 11 March 2013.World Health Organization. Immunization, vaccines and biologicals: rotavirus. 12 April 2010. Retrieved fromhttp://www.who.int/immunization/topics/rotavirus/en/index.html, on 8 March 2013.Reid S. The further and future evolution of the New Zealand Immunisation Schedule. NZ Med J. 2012; 125(1354):86-99.Patel MM, Clark AD, Sanderson CFB, et al. Removing the age restrictions for rotavirus vaccination: a benefit-risk analysis. PLOS Med. 2012;
What do New Zealands healthcare and aviation have in common? Much, if attending to the way non-funded vaccinations are priced. Indeed, I recently needed a two-course rotavirus vaccine for my little one, only to face the equivalent of a return trip offered as two one-way tickets, crippling overcharges and hidden costs.I got multiple quotes, each bringing about a new piece of information; three times I opted out of vaccination because of the ever increasing costs, only to be brought back in when finding alternative quotes online and internationally.In hindsight, however, the experience makes for an interesting case study and provides a provocative insight into the role that Healthcare may be playing in preventing more parents from taking these vaccinations.Methods The sample is a convenient one: the quotes I got during a two-days quest for GlaxoSmithKlines (GSK) dual-dose Rotarix\u00ae. The data are a retrospective breakdown of costs. Hidden costs were estimated as they became apparent.Results I got 12 quotes, 8 from vaccination centres in the North Island (see top of Table 1), 4 from the web and from an international source (bottom of Table 1). The first column lists the chronological order of each quote, the second column lists the initial quote, the last column lists the things I considered when estimating the full cost, broken down in the remaining columns. Consultation fees (free for children) are excluded. Table 1. Breakdown of real and estimated costs quoted for Rotarix\u00ae in 2013 The costs quoted on the Web were made in different years (2009, 2011, 2012) and may not be representative of costs in 2013. Therefore, all costs are standardised to 2010 referential dollars (r$),1 with 2013 nominal values ($) within parentheses when appropriate. The standard quote for comparison is number VII, the still running discounted vaccine* as described in GSKs Patient Access Programme for Rotarix\u00ae,2 and intended to bring about a reduction of r$66 ($69) to the final cost of the vaccine. Considerations This initial quote was the first firm quote paid for. Afterwards, and prior to ordering, the provider realised it had not charged the vaccine correctly, nor GST, delivery costs and nurse's costs. The initial quote turned out to be for one dose. Hidden costs suspected after reading the providers website. Hidden costs not provided but clarified upon questioning. It does not customarily pass delivery fees as a separate cost. It explicitly quoted the full charge for the dual vaccine as applying to each dose separately. It explicitly quoted two delivery fees (yet the two-doses are delivered bundled together). Final price, including vaccine, delivery and service. It explicitly quoted the vaccine as being on special. Quote after asking the provider whether GSK's 2012 programme2 was still running. Rotarix\u00ae's estimated full cost based on information from GSK.2 Rotarix\u00ae's estimated discounted cost based on information from GSK.2 There was a chance this information was outdated. Final price as reflected on the Spanish Vademecum in 2011,3 including vaccine, delivery and service. Simulation of the cost of Rotarix\u00ae in Spain had it been discounted as in New Zealand. Discussion Rotavirus gastroenteritis is quite common, and most children will get infected by the age of 5 years.4 Of these, 3% will need hospitalisation, 6% will be seen by emergency departments, and 20% will be managed at primary care levels.7 The worst cases will course with severe diarrhoea, vomiting, dehydration, electrolyte disturbance,4 brain damage, disability, even death.5 Yet gastroenteritis is preventable5 and the recommended immunisation,4,8-10although not funded,4 may protect up to 90% of children against subsequent severe infections.6 The number of parents opting for non-funded vaccinations is probably low, yet this number may drop further due to the mismatch between actual costs to providers and final costs to parents. Most of the quotes I got in my quest for vaccination largely surpassed the discounted costs intended by GSK by an average of r$97 ($102). Unreasonable practices among providers were quoting the price of the two doses as applicable to each dose individually, as well as quoting two delivery fees, effectively overcharging both. All-in-all, GSKs intention of improving patients access to Rotarix\u00ae2 by bringing about a reduction in the final price of the vaccine to about r$194 ($204)# seems not to be realised, with the consequent detrimental effects on childrens health and future costs to District Health Boards. Footnotes: * GSKs Patient Access Programme for Rotarix\u00ae will run until at least the end of 2013 (personal communication with Melissa Rich, vaccine product manager for GlaxoSmithKline NZ). # A well-organised provider could bring the total cost down to r$173 ($182) by ordering two sets of vaccines at once and passing on the savings in delivery fees. Jose D Perezgonzalez Lecturer, Massey University Palmerston North, New Zealand
Perezgonzalez JD. Referential NZD based on CPI (2012e). Knowledge. 2013: 69-73.Immunisation Advisory Centre. Rotarix\u00ae Patient Access Programme. 20 December 2011. Retrieved from http://www.immune.org.nz/news/rotarix-patient-access-programme, on 10 March 2013.UBM Medica. Vademecum Internacional 11. 2011. Spain: UBM Medica.Ministry of Health. Immunisation Handbook 2011. 2011. Wellington: Ministry of Health.Paediatric Society position statement on Rotavirus immunisation. January 2013. Retrieved from http://www.paediatrics.org.nz/index.asp?pageID=2145878337, on 13 March 2013.Velazquez FR, Matson DO, Calva JJ, et al. Rotavirus infections in infants as protection against subsequent infections. New England J Med. 1996; 335(14):1022-1028.GlaxoSmithKline. GSK submission to the Health Select Committee inquiry into immunisation. N.d. Retrieved from http://www.google.co.nz/url?sa=t&rct=j&q=&esrc=s&source=web&cd=1&cad=rja&ved=0CDAQFjAA&url=http%3A%2F%2Fwww.parliament.nz%2Fnr%2Frdonlyres%2Fdd8706bb-fe39-45af-a146-aabb34613f3a%2F135723%2F49sche_e..&ei=oCpJUcrvI4iaiAfZnIGYBA&usg=AFQjCNH7QbeIeZXstd4uYhC0Ry0XpeAVng&bvm=bv.44011176,d.aGc, on 11 March 2013.World Health Organization. Immunization, vaccines and biologicals: rotavirus. 12 April 2010. Retrieved fromhttp://www.who.int/immunization/topics/rotavirus/en/index.html, on 8 March 2013.Reid S. The further and future evolution of the New Zealand Immunisation Schedule. NZ Med J. 2012; 125(1354):86-99.Patel MM, Clark AD, Sanderson CFB, et al. Removing the age restrictions for rotavirus vaccination: a benefit-risk analysis. PLOS Med. 2012;
The full contents of this pages only available to subscribers.
Login, subscribe or email nzmj@nzma.org.nz to purchase this article.